Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naphak Modhiran

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
The Journal of Infectious Diseases|November 24, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Scientific Reports|February 9, 2021
Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobodyGuillermo Valenzuela Nieto, Ronald Jara, Daniel Watterson, et al.
Science Translational Medicine|December 13, 2019
A recombinant platform for flavivirus vaccines and diagnostics using chimeras of a new insect-specific virusJody Hobson-Peters, Jessica J Harrison, Daniel Watterson, et al.
Nature Aging|November 13, 2023
Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathologyJulio Aguado, Alberto A Amarilla, Atefeh Taherian Fard, et al.
Nature Structural & Molecular Biology|July 8, 2025
A nanobody-based therapeutic targeting Nipah virus limits viral escapeAriel Isaacs, Guillermo Valenzuela Nieto, Xinghai Zhang, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Molecular Psychiatry|November 1, 2022
SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike proteinEduardo A Albornoz, Alberto A Amarilla, Naphak Modhiran, et al.
Vaccines|July 27, 2024
Equal Maintenance of Anti-SARS-CoV-2 Antibody Levels Induced by Heterologous and Homologous Regimens of the BNT162b2, ChAdOx1, CoronaVac and Ad26.COV2.S Vaccines: A Longitudinal Study Up to the 4th Dose of BoosterTatiana A do Nascimento, Patricia Y Nogami, Camille F de Oliveira, et al.
Iscience|June 26, 2023
A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variantsNaphak Modhiran, Simon Malte Lauer, Alberto A Amarilla, et al.
Nature Communications|June 9, 2021
A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA virusesAlberto A Amarilla, Julian D J Sng, Rhys Parry, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
The Journal of Infectious Diseases|November 24, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Scientific Reports|February 9, 2021
Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobodyGuillermo Valenzuela Nieto, Ronald Jara, Daniel Watterson, et al.
Science Translational Medicine|December 13, 2019
A recombinant platform for flavivirus vaccines and diagnostics using chimeras of a new insect-specific virusJody Hobson-Peters, Jessica J Harrison, Daniel Watterson, et al.
Nature Aging|November 13, 2023
Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathologyJulio Aguado, Alberto A Amarilla, Atefeh Taherian Fard, et al.
Nature Structural & Molecular Biology|July 8, 2025
A nanobody-based therapeutic targeting Nipah virus limits viral escapeAriel Isaacs, Guillermo Valenzuela Nieto, Xinghai Zhang, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Molecular Psychiatry|November 1, 2022
SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike proteinEduardo A Albornoz, Alberto A Amarilla, Naphak Modhiran, et al.
Vaccines|July 27, 2024
Equal Maintenance of Anti-SARS-CoV-2 Antibody Levels Induced by Heterologous and Homologous Regimens of the BNT162b2, ChAdOx1, CoronaVac and Ad26.COV2.S Vaccines: A Longitudinal Study Up to the 4th Dose of BoosterTatiana A do Nascimento, Patricia Y Nogami, Camille F de Oliveira, et al.
Iscience|June 26, 2023
A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variantsNaphak Modhiran, Simon Malte Lauer, Alberto A Amarilla, et al.
Nature Communications|June 9, 2021
A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA virusesAlberto A Amarilla, Julian D J Sng, Rhys Parry, et al.
Pageof 8